Overview

POWER Point of Care Effect on Satisfaction of Treatment

Status:
Completed
Trial end date:
2004-11-01
Target enrollment:
Participant gender:
Summary
To compare the subject satisfaction rating in women treated for postmenopausal osteoporosis with Actonel 35mg Once-a-Week for 24 weeks, and receiving feedback information, after 12 weeks of treatment, based on bone resorption marker results using the NTx Point-Of-Care (POC) device, to similar women treated as per regular clinical practice
Phase:
Phase 4
Details
Lead Sponsor:
Sanofi
Collaborator:
Procter and Gamble
Treatments:
Risedronate Sodium
Risedronic Acid